IVAX Corporation engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It offers respiratory drugs primarily for bronchial asthma, including a breath-operated inhaler called BREATHMATICa in the United States; Easi-Breathe in other countries; and a dry powder inhaler, as well as metered-dose inhalers. The company also develops various inhalation products, such as chlorofluorocarbon-free inhalation aerosol products; Xorane; TP-38; Cervene; and Talampanel. As of December 31, 2004, IVAX manufactured and marketed approximately 73 brand equivalent prescription drugs in capsule or tablet forms in an aggregate of approximately 169 dosage strengths. As of the same date, it distributed approximately 168 additional brand equivalent prescription and over-the-counter drugs, and vitamin supplements in the United States. The company offers its products to wholesalers, retail drug chains, retail pharmacies, mail order companies, physicians, pharmacies, hospitals, managed health care organizations, and government agencies. IVAX was founded in 1972 and is headquartered in Miami, Florida. As of January 26, 2006 IVAX Corporation is a subsidiary of Teva Pharmaceutical Industries Ltd.